Alvotech resubmits BLAs for AVT05 and AVT06, but core manufacturing and financial risks persist

What happened

Alvotech resubmitted U.S. Biologics License Applications for AVT05 (golimumab) and AVT06 (aflibercept) on June 4, 2026, following a November 2025 complete response letter for AVT05 that highlighted persistent manufacturing deficiencies at its single Reykjavik facility. The resubmission is a procedural necessity but does not confirm that FDA’s underlying quality concerns have been resolved, and the company still faces negative equity, ~$1.1B in secured debt, and material weaknesses in internal controls. While European approvals for related assets (AVT03, Mynzepli) provide some revenue diversification, the U.S. market remains critical for deleveraging, and any further FDA setbacks could trigger covenant stress. The stock has already fallen ~65% from early 2025 levels, reflecting the market’s skepticism about execution reliability and balance sheet strength. This development keeps the stock in a wait-and-see zone until concrete evidence of regulatory compliance and sustainable free cash flow emerges.

Implication

The resubmission of AVT05 and AVT06 BLAs is a necessary milestone but does not alter the fundamental thesis: Alvotech must demonstrate that its Reykjavik facility can consistently pass FDA scrutiny and that product revenue can drive positive free cash flow to service ~$1.1B in debt. The market already prices in a high probability of failure, but the risk of another CRL or liquidity event remains material. Investors should monitor the FDA's acceptance decision and any inspection outcome in the coming months. Only if the resubmission leads to a timely approval and the company shows improving free cash flow should one consider upgrading the rating. Until then, the asymmetric downside from manufacturing and balance sheet risks outweighs the potential upside from a successful launch.

Thesis delta

The AVT05/AVT06 resubmission is a positive procedural step but does not resolve the core thesis risks: single-site FDA compliance, high leverage, and negative equity. The call remains on hold, pending tangible proof of manufacturing remediation and cash generation. No material change to the base-case bearish tilt.